HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Testa, L. Articles by Banning, A.P. Search for Related Content PubMed Articles by Testa, L. Articles by Banning, A.P. Related Collections Cardiac - pharmacology Coronary disease Extracorporeal circulation Myocardial protection

J Thorac Cardiovasc Surg 2008;136:884-893
© 2008 The American Association for Thoracic Surgery

Surgery for Acquired Cardiovascular Disease

Pexelizumab in ischemic heart disease: A systematic review and meta-analysis on 15,196 patients

^a Institute of Cardiology, John Radcliffe Hospital, Oxford, United Kingdom
^b Division of Cardiology, University of Turin, Turin, Italy
^c Department of Medicine, Virginia Commonwealth University, Richmond, Va
^d Antwerp Cardiovascular Institute Middelheim, AZ Middelheim, Antwerp, Belgium
^e Institute of Cardiology, Catholic University, Rome, Italy

Received for publication October 10, 2007; accepted for publication December 14, 2007.

^_* Address for reprints: Luca Testa, MD, PhD, FEAPCI, Cardiology Ward, Level 2, John Radcliffe Hospital, Headley Way, Oxford, OX3 9DU, United Kingdom. (Email: luctes{at}gmail.com).

Object: Pexelizumab is a humanized monoclonal antibody inhibiting C5 complement. It has been postulated to improve outcomes in patients undergoing coronary artery bypass surgery and urgent reperfusion therapy for ST elevation myocardial infarction. We aimed at evaluating the risk/benefit profile of pexelizumab (bolus + infusion) versus placebo on top of current approaches in the management of patients with ST elevation myocardial infarction or undergoing coronary artery bypass.

Methods: We conducted a search of BioMedCentral, CENTRAL, mRCT, and PubMed without language restrictions (updated October 2007) for randomized controlled trials. Outcomes of interest were the risk of major adverse events (the composite of all-cause death, myocardial infarction, and thromboembolic stroke), the risk of single end points, and heart failure.

Results: Seven trials were included (15,196 patients: 7019 patients with ST elevation myocardial infarction and 8177 undergoing coronary bypass surgery). No benefit of adding pexelizumab was found in the overall analysis for major adverse events (OR 0.91 [0.76–1.09]; P = .29], death (OR 0.79 [0.61–1.03], P = .11], myocardial infarction (OR 1.04 [0.89–1.22]; P = .14), stroke (OR 0.95 [0.66–1.38]; P = .8), heart failure (OR1.0 [0.82–1.22]; P = .99), nor in the settings of patients with ST elevation myocardial infarction treated with mechanical or pharmacologic reperfusion therapy. Pexelizumab was associated with a 26% reduction of the risk of death in the setting of coronary artery bypass (OR 0.74 [0.58–0.94]; P = .01). The number needed to treat was 100.

Conclusion: Our data ruled out the hypothesis of any benefit of adding pexelizumab on top of currently available therapies for ST elevation myocardial infarction. However, pexelizumab reduces the risk of death in patients undergoing coronary artery bypass grafting.

This article has been cited by other articles:

				D. Ricklin and J. D. Lambris Complement in Immune and Inflammatory Disorders: Therapeutic Interventions J. Immunol., April 15, 2013; 190(8): 3839 - 3847. [Abstract] [Full Text] [PDF]

				L. Timmers, G. Pasterkamp, V. C. de Hoog, F. Arslan, Y. Appelman, and D. P. V. de Kleijn The innate immune response in reperfused myocardium Cardiovasc Res, May 1, 2012; 94(2): 276 - 283. [Abstract] [Full Text] [PDF]

				Writing Committee Members, L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J. Thorac. Cardiovasc. Surg., January 1, 2012; 143(1): 4 - 34. [Full Text] [PDF]

				L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, A. M. Hutter Jr, et al. Special Article: 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Anesth. Analg., January 1, 2012; 114(1): 11 - 45. [Full Text] [PDF]

				Writing Committee Members, L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, December 6, 2011; 124(23): e652 - e735. [Full Text] [PDF]

				Writing Committee Members, L. D. Hillis, P. K. Smith, J. L. Anderson, J. A. Bittl, C. R. Bridges, J. G. Byrne, J. E. Cigarroa, V. J. DiSesa, L. F. Hiratzka, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, December 6, 2011; 124(23): 2610 - 2642. [Full Text] [PDF]

				M. S. Haas, E. M. Alicot, F. Schuerpf, I. Chiu, J. Li, F. D. Moore, and M. C. Carroll Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction Cardiovasc Res, September 1, 2010; 87(4): 618 - 627. [Abstract] [Full Text] [PDF]

				U. Hofmann, J. Bauersachs, and S. Frantz Nothing but natural: targeting natural IgM in ischaemia/reperfusion injury Cardiovasc Res, September 1, 2010; 87(4): 589 - 590. [Full Text] [PDF]

				W. M. van den Bergh Is There a Future for Neuroprotective Agents in Cardiac Surgery? Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2010; 14(2): 123 - 135. [Abstract] [PDF]

				C. Hoedemaekers, M. van Deuren, T. Sprong, P. Pickkers, T.-E. Mollnes, I. Klasen, and J. van der Hoeven The Complement System Is Activated in a Biphasic Pattern After Coronary Artery Bypass Grafting Ann. Thorac. Surg., March 1, 2010; 89(3): 710 - 716. [Abstract] [Full Text] [PDF]